Conference Venue (2) - International Society of Microbiota

Who is Attending Targeting Microbiota 2024?

2024-04-17T11:34:44+00:00

Academia Sinica
AccessMDx
A&P Inphatec
Aalborg University
Asan Medical Center
Beneficial Microbes
Petsiavas

BG KlinikumBergmannstrost Halle

Charité Research Organisation GmbH
Copan Italia Spa
ETH Zurich
Herbalife Nutrition
Hirszfeld Institute of Immunology and Experimental Therapy
ILVO
Institute of Human Genetics Polish Academy of Sciences
Institute of Microecology
Instituto de Investigación nutricional
IUF - Leibniz Research Institute for Environmental Medicine
IUF Düsseldorf
JHJ Poland
Kinderarztpraxis Arlt-Bonakdar
Laval University
L'Oréal

Maastricht University
McMaster University
North Denmark Regional Hospital
Masaryk university
Örebro University
PANACEA
Polish Academy of Sciences
RIKEN Center for Integrative Medical Sciences
Sidra Medicine
Università degli Studi di Milano-Bicocca
Universitat de Girona
Université de Montréal/CHUM
University Gent
University of Aberdeen
University of Guadalajara
University of Life Sciences in Lublin
University of Milan
University of Oulu
University of Ulm
University of Veterinary Medicine and Pharmacy in Košice, Slovekia
Zentiva
University of Southampton Hospital

17/05/2024

Targeting Microbiota 2024: Confirmed Speakers

2024-03-01T11:42:09+00:00

Keynote Speech Day 1
Phage Therapy: A New Era of “Old” Concept for “Microbiome” Health
Mzia Kutateladze, Eliava Institute of Bacteriophage, Georgia

Keynote Speech Day 2
The Mystery of the Microbiome Genome: The Potential of 2 to 20 Million Microbial Genes to Transform Our Health
Marvin Edeas, Institut Cochin, INSERM U1016, Université de Paris, France

Gut Microbiome, Obesity and Diabetes
Hiroshi Ohno, RIKEN Center for Integrative Medical Sciences, Japan

Mythbusting Our Microbiome
Alan Walker, University of Aberdeen, United Kingdom

Probiotics & Health: How to Select the Right Strain?
Andreas Schwiertz, Institute of Microecology, Germany

Gut Brain Axis & Depression: Startegic Role of Dietary Proline Exposed
José Manuel Fernández-Real, Institut d'Investigació Biomèdica de Girona, Hospital Trueta de Girona, and University of Girona, Spain

The Small Intestinal Microbiota: A Hidden Player in Human Health and Disease
Pascale Vonaesch, University of Lausanne, Switzerland

Microbiota-Derived Extracellular Vesicles: Bridging Mother and Fetus
Justus Reunanen, University of Oulu, Finland

Male Fertility And Gut Microbiota: Current Knowledge And Future Directions
Cristian O'Flaherty, McGill University, Canada

Microbial Phenotypes in Obesity: Implications for Precision Nutrition
Ellen Blaak, Maastricht University, Netherlands

Bacteriophages Redesigned – Tiny Killers and Detectives to Support Infectious Disease Therapy
Martin Loessner, ETH Zurich, Switzerland

Prospects for Leveraging the Microbiota as Medicine for Hypertension
Bina Joe, University of Toledo, USA

Sophisticated in vitro Models of the Gastrointestinal Tract to Study the Role of the Gut Microbiota in Health and Disease
Koen Venema, Editor-in-chief of Beneficial Microbes, Netherlands

Gut Microbiota in Early Life: Impact on Neurodevelopmental Outcomes
Rochellys Diaz Heijtz, Karolinska Institutet, Sweden

Gut Bacteria and Heart Healing: The Hidden Players in Post-Infarction Resilience
Patrick C. H. Hsieh, Academia Sinica, Tawian

The Oral-Placental Microbiome Axis in Preterm Birth
Souhaila Al Khodor, Sidra Medicine, Qatar

Gut Microbiome Signatures in Irritable Bowel Syndrome
Simone Domenico Guglielmetti, Università degli Studi di Milano-Bicocca, Italy

From Microbiomes and (Meta)genomes to the Lab and Back - Identification, Production and Application of Bacteriocins
Christian Riedel, University of Ulm, Germany

Targeting Microbiota 2024 Sessions

2024-01-22T16:57:10+00:00

Day 1 - Monday, October 14, 2024

Key note Speaker:
Targeting Gut and Skin by Phages: Towards the Next Clinical Revolution

Session 1:
Microbiota in Health & Disease: Advancements & Perspectives

a. Fecal Microbiota Transplantation (FMT): Clinical Applications, Regulation and Insights

b. Probiotics in Health & Disease Management: Strain-Specific Efficacy and Challenges

c. Metabolites Analysis: Characterization and Synthetic Approaches for Clinical and Nutritional Research

d. Phage Therapy: Emerging Applications and Challenges

e. Extracellular Vesicles and Exosomes: Where is the Target?

Day 2 - Tuesday, October 15, 2024

Session 2:
Probiotic & Prebiotic Prescribing Practices: How to Empower Medical Actors to Improve Patients' Health?

How Can We Integrate the Latest Research for Optimal Results?
What Are the Challenges and Opportunities in Current Probiotic Use?
How Can Next-Generation Probiotics Transform Patient Care?

This specialized workshop will target medical professionals including cardiologists, neurologists, oncologists and others.

International Society of Microbiota
Press Releases | LinkedIn | Facebook

Targeting Microbiota 2024 - Malta Venue and Travel Information

2023-12-07T10:17:44+00:00

Event Location

Venue: Corinthia Palace
Address: De Paule Avenue, BZN 9023 San Anton, Malta

Hotel's website.

Book your room at a preferential rate

The ISM secured limited rooms with a preferential rate at the conference hotel, Corinthia Palace Malta, for its attendees.

Book your room now as they are limited!

Airport

Malta International Airport: Located between Luqa and Gudja, 10 km from Valletta.

For more information about the airport, click here.

Passports & Visas

For visa application information, please visit the Maltese Ministry for Foreign Affairs website.

Transports in Malta

For details on various transport options in Malta, please click here.

More about Malta

Discover Malta

Experience 7000 years of history and vibrant contemporary life.
Malta is known for its striking contrast of honey-coloured stone against the Mediterranean blues.
Rich in history, from prehistoric times to the era of St. Paul and the Knights of St. John.
Malta offers a variety of activities: sports, historic site tours, nightlife, and wellness.
The sister islands, Gozo and Comino, provide a relaxed, holiday-within-a-holiday experience.

Accommodation and Activities

Malta has a range of accommodations and activities to cater to all tastes, including luxury hotels and diverse sporting and leisure opportunities.

Getting Around

Malta offers convenient transport options for exploring the islands' rich history, culture, and natural beauty.

Know more about Malta Tourism and Visits to do.

Targeting Microbiota 2023 Highlights

2023-10-23T10:02:28+00:00

Targeting Microbiota 2023 Photo Gallery

Targeting Microbiota 2023 Replay & Abstracts Book are Available

2023-10-16T09:20:26+00:00

Targeting Microbiota 2023 - Replay Access

Targeting Microbiota 2023 Recordings are now available for replay. You can get access to all recorded presentations for 3 weeks. On-demand content make it easier for you to access the presentations at your convenience.

22 hours of presentations on Microbiota

62+ presentations (major talks and short orals)

Order 3-weeks Replay Access.

Targeting Microbiota 2023 Abstracts Book

The 10th edition of Targeting Microbiota digital abstracts book compiles 62+ abstracts: from major talks to Short Oral and Poster Presentations. It also includes speaker details and emails for direct connections.

Order Abstracts Book.

Targeting Microbiota 2023 Congress - Replay + Abstracts Book

You can benefit from Targeting Microbiota 2023 Recording access + Abstract Book together for a clearer vision and a better Targeting Microbiota Conference experience.

Order both abstracts book and the replay.

Phage-Microbiome Consortium: Interplay and Modulation in Human Health and Disease

2023-09-26T14:20:51+00:00

The ISM is pleased to announce the launch of The Phage-Microbiome Consortium.

Aim of the Consortium

The aim of this project is to set up a consortium of experts in the field of bacteriophages and the human microbiome, to collectively explore the potential of phages in shaping and modulating the microbiome in the context of human health and disease. The consortium will work in teams to push the boundaries of current knowledge, through collaborative research and knowledge exchange.

Objectives

1. Understand the Phage-Microbiota Interaction:
The consortium will carry out integrated studies to enhance the understanding of phage-bacteria dynamics and the role of phages in maintaining microbial diversity and stability.

2. Explore the Potential of Phage Therapy:
Teams will investigate the potential of phages as alternative therapeutic agents for various diseases, focusing particularly on conditions associated with microbiome dysbiosis and antibiotic resistance.

3. Identify Phage Biomarkers:
The consortium will work to identify specific changes in phage populations associated with different health conditions, thus facilitating disease prediction, diagnosis, and treatment.

4. Promote Phage Engineering:
With advancements in genetic engineering, the consortium will explore possibilities to create engineered phages with enhanced efficiency, broader spectrums, and other desirable properties.

5. Establish Regulatory and Safety Guidelines:
Recognizing the lack of robust regulatory guidelines for phage therapy, the consortium will also work towards proposing safe and effective guidelines.

What is expected?

The expected outcome of this project is to offer new insights into the complex interplay between phages and the human microbiome and to pave the way for innovative, effective, and personalized phage therapies. By bridging the expertise gap, we aim to leverage the immense potential of phages in treating diseases and promoting human health.

Project Modalities and Application Procedure

To contribute to this Consortium, the ISM requests interested researchers and teams to submit a proposal. Below are the guidelines to respect:

1. Team Formation:
Interested teams should consist of a diverse range of experts with substantial knowledge and experience in bacteriophages, microbiota, or related fields. Each team should ideally have at least one expert in bacteriophages and one in microbiota.

2. Proposal Submission:
Teams should submit a detailed project proposal that outlines their planned research, including objectives, methodologies, expected outcomes, and the timeline for the project. Proposals should demonstrate a clear understanding of the interplay between phages and the microbiome and should propose innovative approaches to explore and modulate this relationship in the context of human health and disease. They should also clearly state how the work contributes to the broader objectives of the consortium.

3. Review Process:
Proposals will be reviewed by a panel of experts in the field. Successful proposals will be selected based on their scientific merit, feasibility, and potential impact on our understanding of the phage-microbiome interplay.

Funding

The consortium will actively seek funding from both private and public institutions to support the selected projects. The collected funding will be distributed to all teams involved in the Consortium.

How to Submit?

Please submit your projects and details above:

- At the following email address: microbiota(at)microbiota-site.com.

- Deadline for the submission: October 1, 2024.

Applications will be reviewed by the Consortium Selection Committee, and successful applicants will be contacted to proceed to the next stage of the process. Please note that acceptance into the consortium is competitive, and only a select number of applicants will be chosen to join.

Role of the International Society of Microbiota

The International Society of Microbiota will act as the principal coordinator and manager of this consortium. The Society will facilitate the integration of teams and will foster the exchange of knowledge and expertise amongst the participants.

In its role as coordinator, the Society will ensure that all projects align with the consortium's overarching goals. It will provide guidance and direction to ensure that research efforts are complementary and additive. The Society will also help in harmonizing data collection and sharing across teams to promote a more comprehensive understanding of the phage-microbiome relationship.

The ISM, will supervise the allocation and utilization of consortium-provided funds, ensuring they are used effectively and efficiently. It will liaise with private and public funding institutions, advocating for the consortium's work and securing additional resources.

Through this central role, the International Society of Microbiota aims to unite global expertise and drive forward the understanding of the pivotal role of phages in modulating the microbiome and influencing human health and disease.

International Society of Microbiota
Targeting Microbiota 2023 Congress
October 17-19, 2023 - Venice

About the ISM Phage-Microbiome Consortium

2023-08-24T12:32:40+00:00

The newly launched Phage-Microbiome Consortium of the ISM aims to offer new insights into the complex interplay between phages and the human microbiome and to pave the way for innovative, effective, and personalized phage therapies. The ISM invites all interested parties to submit proposals & join the consortium.

Abstract & Project Submissions

2023-08-04T16:09:05+00:00

The International Society of Microbiota (ISM) invites researchers, healthcare professionals, industry experts, and startups to submit abstracts and project proposals that align with the conference’s themes and objectives. This is an excellent opportunity to share your cutting-edge research, innovative projects, and impactful ideas with a global audience.

Targeting Microbiota 2023 is excited to host an Innovation Showcase, providing a dedicated platform for startups, industry leaders, and innovators to demonstrate their groundbreaking technologies, products, and services in the field of microbiota research.

2 submission types are available:

1. Regular Abstract Submission

Researchers and professionals are encouraged to submit abstracts highlighting their work in the field of microbiota. Abstracts should provide a concise summary of the research objectives, methods, key findings, and their implications in future research. Accepted abstracts will be presented as posters or oral presentations during the conference sessions, allowing participants to showcase their work and engage in fruitful discussions.

Targeting Microbiota 2023 is also excited to host an Innovation Showcase, providing a dedicated platform for startups, industry leaders, and innovators to demonstrate their groundbreaking technologies, products, and services in the field of microbiota research. Participants in the Innovation Showcase will have the chance to showcase their products through interactive displays, demonstrations, and presentations.

Deadline for Oral Presentations Submission: September 30, 2023.

Deadline for Innovation Submission: September 30, 2023.

Deadline for Posters Presentations Submission: October 7, 2023.

Submission Guidelines & Modalities.

2. Project Proposals

In addition to abstract submissions, the conference welcomes project proposals that offer new insights into the complex interplay between phages and the human microbiome and to pave the way for innovative, effective, and personalized phage therapies. Proposals should outline the project’s objectives, methodologies, expected outcomes, and potential impact in the field. Accepted project proposals may have the opportunity to be featured in dedicated sessions or workshops during the conference, providing a platform to discuss and collaborate with other participants.

Learn more about the Phage-Microbiome Consortium.

Deadline for Project Proposal Submission: September 1, 2023.

Who Attended Targeting Microbiota 2023?

2023-05-26T11:29:30+00:00

Industries

BellaVie

BIOCODEX

Bioscientifica

Copan Italia SpA

Dr. Schär

Gnosis by LeSaffre

ImmunoBiome

L'Oréal R&I

MedibiotiX GmbH

SYNLAB MVZ Leinfelden-Echterdingen

Unifarco Spa

Uwe Zeeb Gebäudedienste & Umwelttechnik

Vet-Med-Labor Zrt.

Percheron Bioceutical

Academies

Academy of Silesia, Gyncentrum sp. z o.o.
Acibadem Maslak Hospital, Dept Obstetrics & Gynecology
Aristotle University of Thessaloniki
Baylor College of Medicine
BiomedicalCenter Speyer
BMR GENOMICS SRL
Clinical Microbiomics
Department of Experimental Biology, Faculty of Science, Masaryk University
DPC Hospital
East Lancashire Hospitals NHS Trust
Evomed Luxembourg
FISABIO
Florida International University
Furtwangen University of Applied Sciences
Herbalife Nutrition
INIBIC
INRAe
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade
Instituto Nacional de Saúde Dr Ricardo Jorge
Institutul Clinic Fundeni
Kaiserlautern University of Applied Sciences
Karolinska Institutet
Korea Food Research Institute
Korea Research Institute of Bioscience & Biotechnology
KU Leuven
LAMPOVET SRL
LUHS Hospital Kaunas Clinics
Masaryk University, Faculty of Science
Masarykova univerzita
Massachusetts General Hospital

Mayo Clinic

Medical Treatment Center of Microbial Medicine
Medical University of Warsaw
MHB
Microbiology Laboratory, Medical School of A.U.Th.
National University of Singapore
Nofima

PI "National Laboratory Astana"
Practice for Internal Medicine
Queen's University Belfast - SBS
Samsung Advanced Institute for Health Sciences and Technology
sc centrul medical unirea srl
Scuola Normale Superiore
SEMMELWEIS UNIVERSITY
Shree Ramkrishna Intitute of computer education and Applied Science
St. Anne's University Hospital in Brno
Sungkyunkwan University
TargEDys
Teaching Hospital of the University of Jena
The Chinese University of Hong Kong
The Institute of Microbiome and Applied Science
The Seventh Affiliated Hospital of Southern Medical University
The University of Chicago
UGent
United Arab Emirates University
Universidade de Santiago de Compostela
Università Ca' Foscari Venezia
Universitat Rovira i Virgili
University College London
University of Arkansas
University of Bologna
University of Copenhagen
University of Florida
University of Genoa
University of Gothenburg
University of Lausanne
University of Leipzig
University of Medicine and Pharmacy "Grigore T. Popa"
University of Padova
University of Pennsylvania
University of Texas Southwestern Medical Center
University of Zagreb School of Medicine, Center for Translational and Clinical Research
USDA-ARS Poultry Production and Product Safety Research Unit
Weill Cornell Medicine in Qatar